Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

The usual beginners' dose of Mounjaro is 2.5 milligrams once ... If you’re interested in the Ozempic vs. Wegovy vs. Mounjaro debate, you might be wondering where you can buy them.

She was prescribed compound semaglutide, a cheaper, custom-made version of the active drug in Ozempic and Wegovy ... So she cut back on her dosage after surgery and eventually forgot to take ...

Zealthy Weight Loss Overview Cost: $49 for your first month and $135 per month thereafter Types of weight loss medications: ...

The Biden administration moved Friday to negotiate the prices Medicare pays for the blockbuster weight-loss drugs Ozempic and Wegovy ... pills in half or skip a dose in their prescription so ...